Researchers discover 'Holy Grail' of cancer treatment

March 24, 2016 by Caleb Radford

Researchers are developing nanotech "smart packages" to target and destroy cancer cells more efficiently and reduce side effects.

The smart packages, delivered with chemotherapy drugs, contain folate molecules that seek out and bind to , which have lower pH levels than healthy cells.

The packages then release anti-cancer drugs to kill the targeted cells without harming in the vicinity.

Professor Colin Raston from Flinders University in South Australia is co-leading the research and said the innovative new system would revolutionise how cancer was treated.

"It is the holy grail of medicine," Prof Raston said.

"The way we have designed the vehicle is that you can use it for any number of different cancer cells or combination of different cancer cells. You can load it up and target them using specific types of drugs, which we know are for those particular cancers."

The small delivery "vehicles" are 100 nanometres in diameter, almost 800 times finer than a human hair, the ideal size for targeting tumours.

"Along the ends of the vehicle are folate molecules that bind to the cancer cell. When it strikes the cells, all of which have low pH levels, it becomes unstable and delivers the anti-cancer drug inside," Prof Raston said.

"The problem with conventional therapy is most of it ends up in sewage. That's a problem, but if you have targeting drug therapy then you only need a small amount of the drug.

"This way you are not polluting the sewage and you are also shutting down all the side effects."

Prof Raston said the research so far had been cell work, but researchers were almost ready to advance to the next phasestage of development.

Lung cancer is the most common cancer in the world, with more than 1.8 million new cases a year. In 2012, the World Cancer Research Fund International reported almost 240,000 cases of ovarian cancer and more than 14 million total cancer cases worldwide. This number is expected to increase to 24 million by 2035.

The research was conducted in collaboration with Dr Jingxin Mo from China's Sun Yat-sen University and Professor Lee Yong Lim from the University of Western Australia.

The proof of concept paper, entitled Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform has been published in Scientific Reports.

Explore further: Vortex device makes for better cancer treatments

More information: Jingxin Mo et al. Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform, Scientific Reports (2016). DOI: 10.1038/srep23489

Related Stories

Vortex device makes for better cancer treatments

May 22, 2015
A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer.

Research identifies first step in design of new anti-cancer drugs

March 9, 2016
New research has identified a first step in the design of a new generation of anti-cancer drugs that include an agent to inhibit resistance to their effectiveness.

Drug combination shuts down cancer stem cells and tumor growth in aggressive lung cancer

March 14, 2016
Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.

Researchers find a genetic new target for most common lung cancer

March 22, 2016
Research in Manchester has identified mutations in lung cancer that is key to tumour growth, offering a new way to differentiate and treat some patients with the disease.

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.